Screening for hepatocellular carcinoma: Survival benefit and cost-effectiveness

Annals of Oncology

Volumn 14, Issue 10, 2003, Pages 1463-1467

  Yuen, M F ^a   Lai, C L ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

fetoprotein; Cost effectiveness; Hepatocellular carcinoma; Survival; Ultrasonography

Indexed keywords

ALPHA FETOPROTEIN;

CANCER INCIDENCE; CANCER RISK; CANCER SCREENING; CANCER SURVIVAL; CANCER THERAPY; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; ECHOGRAPHY; HIGH RISK PATIENT; HUMAN; LIVER CELL CARCINOMA; MEDICAL LITERATURE; MEDLINE; NON INVASIVE MEASUREMENT; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SENSITIVITY AND SPECIFICITY;

ADULT; AGE FACTORS; AGED; ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; COST-BENEFIT ANALYSIS; HUMANS; LIVER NEOPLASMS; MASS SCREENING; MIDDLE AGED; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; ULTRASONOGRAPHY;

EID: 0142248269     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdg400     Document Type: Review

References (38)

1. World Health Organization. Prevention of Liver Cancer. WHO technical report series. Geneva: WHO 1993.
2. Kew MC. Hepatocellular carcinoma. A century of progress. Clin Liver Dis 2000; 4: 257-268.
3. Collier J, Sherman M. Screening for hepatocellular carcinoma. Hepatology 1998; 27: 273-278.
4. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340: 745-750.
5. Lai CL, Lau JY, Wu PC et al. Subclinical hepatocellular carcinoma in Hong Kong. Chinese Oncology 1992; 49: 347-353.
6. Lai CL, Lam KC, Wong KP et al. Clinical features of hepatocellular carcinoma: review of 211 patients in Hong Kong. Cancer 1981; 47: 2746-2755.
7. Wilson JHG, Junguer G. The Principles and Practice of Screening for Disease. Public Health Papers 34. Geneva: WHO 1968.
8. Sherman M, Peltekian KM, Lee C. Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North American urban population. Hepatology 1995; 22: 432-438.
9. Yuen MF, Cheng CC, Lauder IJ et al. Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience. Hepatology 2000; 31: 330-335.
10. Okuda K, Kotoda K, Obata H et al. Clinical observation during a relatively early stage of hepatocellular carcinoma, with special reference to serum α-fetoprotein levels. Gastroenterology 1975; 69: 226-234.
11. Chen DS, Sung JL, Sheu JC et al. Serum α-fetoprotein in the early stage of human hepatocellular carcinoma. Gastroenterology 1984; 86: 1404-1409.
12. Trevisani F, D'Intino PE, Morselli-Labate AM et al. Serum α-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol 2001; 34: 570-575.
13. Lok ASF, Lai CL. α-fetoprotein monitoring in Chinese patients with chronic hepatitis B virus infection: role in the early detection of hepatocellular carcinoma. Hepatology 1989; 9: 110-115.
14. Larcos G, Sorokopud H, Berry G et al. Sonographic screening for hepatocellular carcinoma in patients with chronic hepatitis or cirrhosis: an evaluation. Am J Roentgenol 1998; 171: 433-435.
15. Okazaki N, Yoshida T, Yoshino M et al. Screening of patients with chronic liver disease for hepatocellular carcinoma by ultrasonography. Clin Oncol 1984; 10: 241-246.
16. Bolondi L, Sofia S, Siringo S et al. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut 2001; 48: 251-259.
17. Sherman M. α-Fetoprotein: an obituary. J Hepatol 2001; 34: 603-605.
18. Tremolda F, Benevegnu L, Drago C et al. Early detection of hepatocellular carcinoma in patients with cirrhosis by α-fetoprotein, ultrasound and fine-needle biopsy. Hepatogastroenterology 1989; 36: 519-521.
19. Caturelli E, Bartolucci F, Biasini E et al. Diagnosis of liver nodules observed in chronic liver disease patients during ultrasound screening for early detection of hepatocellular carcinoma. Am J Gastroenterol 2002; 97:397-405.
20. Pateron D, Ganne N, Trinchet JC et al. Prospective study of screening for hepatocellular carcinoma in Caucasian patients with cirrhosis. J Hepatol 1994; 20: 65-71.
21. Sheu JC, Sung JL, Chen DS et al. Growth rate of asymptomatic hepatocellular carcinoma and its clinical implications. Gastroenterology 1995; 89: 259-266.
22. McMahon BJ, Bulkow L, Harpster A et al. Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: a 16-year population-based study. Hepatology 2000; 32: 842-846.
23. Trevisani F, De Notariis S, Rapaccini G et al. Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience). Am J Gastroenterol 2002; 97: 734-744.
24. Kang JY, Lee TP, Yap I et al. Analysis of cost-effectiveness of different strategies for hepatocellular carcinoma screening in hepatitis B virus carriers. J Gastroenterol Hepatol 1992; 7: 463-468.
25. Yang B, Zhang B, Xu Y et al. Prospective study of early detection for primary liver cancer. J Cancer Res Clin Oncol 1997; 123: 357-360.
26. Colombo M, De Franchis R, Del Ninno E et al. Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med 1991; 325: 675-680.
27. Fasani P, Sangiovanni A, De Fazio C et al. High prevalence of multinodular hepatocellular carcinoma in patients with cirrhosis attributable to multiple risk factors. Hepatology 1999; 29: 1704-1707.
28. Unoura M, Kaneko S, Matsushita E et al. High-risk groups and screening strategies for early detection of hepatocellular carcinoma in patients with chronic liver disease. Hepatogastroenterology 1993; 40: 305-310.
29. Tang ZY, Yu YQ, Zhou XD et al. Subclinical hepatocellular carcinoma: an analysis of 391 patients. J Surg Oncol 1993; 3 (Suppl): 55-58.
30. Cottone M, Turri M, Caltagirone M et al. Screening for hepatocellular carcinoma in patients with Child's A cirrhosis: an 8-year prospective study by ultrasound and α-fetoprotein. J Hepatol 1994; 21: 1029-1034.
31. Zoli M, Magalotti D, Bianchi G et al. Efficacy of a surveillance program for early detection of hepatocellular carcinoma. Cancer 1996; 78: 977-985.
32. Solmi L, Primerano AM, Gandolfi L. Ultrasound follow-up of patients at risk for hepatocellular carcinoma: results of a prospective study on 360 cases. Am J Gastroenterol 1996; 6: 1189-1194.
33. Farinati F, Gianni S. Surveillance for hepatocellular carcinoma in cirrhosis: is it cost-effective? Ear J Cancer Prev 2001; 10: 111-115.
34. Wong LL, Lim WM, Severino R et al. Improved survival with screening for hepatocellular carcinoma. Liver Transpl 2000; 6: 320-325.
35. Sarasin FP, Giostra E, Hadengue A. Cost-effectiveness of screening for detection of small hepatocellular carcinoma in western patients with Child-Pugh class A cirrhosis. Am J Med 1996; 101: 422-434.
36. Bruix J, Llovet JM. Hepatocellular carcinoma: is surveillance cost effective? Gut 2001; 48: 149-150.
37. Yuen MF, Lai CL. Natural history of chronic hepatitis B virus infection. J Gastro Hepatol 2000; 15 (Suppl): E20-E24.
38. Chen DS. Natural history of chronic hepatitis B virus infection: new light on an old story. J Gastro Hepatol 1993; 8: 470-475.